Sepracor, Inc.

University of Massachusetts

John R McCullough

Thomas P Jerussi

Vincent L Fabiano

Emil R Smith

Gunnar Aberg

A K Gunnar Aberg

A K Aberg

Chris Hugh Senanayake

Gerald J Tanoury

Yaping Hong

Patrick Koch

Paul D Rubin

Qun Kevin Fang

Chrisantha Hugh Senanayake

Ak Gunnar Aberg

Yue Fang

Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.

Compositions of descarboethoxyloratadine

Methods for the treatment of allergic rhinitis

Methods for treating urticaria using descarboethoxyloratadine

Compositions and methods utilizing the optically pure (&plus;) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (&plus;) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (&plus;) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

Compositions of optically pure (&plus;) norcisapride

Methods and compositions are disclosed utilizing the optically pure (&plus;)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (&plus;)-bupropion

Methods and compositions for treating chronic disorders using optically pure (&plus;)-bupropion

A method of preparation of optically pure isomers of hydroxyitraconazole, in particular the two cis dioxolane diastereomers of the sec-butyl (S,S)-isomer, and to phosphate and sulfate derivatives thereof is disclosed. Pharmaceutical compositions containing these compounds and to their use for the treatment of fungal infection are also disclosed.

2R,4S,S,S- and 2S,4R,S,S-hydroxyitraconazole

Methods are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, cerebral function disorders, cigarette smoking, and incontinence.

Bupropion metabolites and methods of use

Compositions are disclosed utilizing the optically pure (&minus;) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dyspepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (&minus;) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.

Compositions of optically pure (&minus;) norcisapride

Compositons employing and methods utilizing the optically pure (&plus;) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (&plus;) norcisapride, has also been found to be a potent antiemetic agent. Finally the (&plus;) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R)-trihexyphenidyl. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, substantially free of the (S)-trihexyphenidyl enantiomer. Pharmaceutical compositions for the treatment of urinary incontinence comprising enantiomerically enriched (R)-trihexyphenidyl, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.

Methods and compositions for treating urinary incontinence using enantiomerically enriched (R)-trihexyphenidyl

A method for treating urinary incontinence, such as incontinence resulting from bladder detrusor muscle instability, using enantiomerically enriched (R, R)-glycopyrrolate. The method comprises administering a therapeutically effective amount of enantiomerically enriched (R, R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, substantially free of the (S, S)-glycopyrrolate enantiomer. Pharmaceutical compositions for the treament of urinary incontinence comprising enantiomerically enriched (R, R)-glycopyrrolate, or a pharmaceutically acceptable salt thereof, and an acceptable carrier are also disclosed.

Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate

A method of preparation of optically pure isomers of hydroxyitraconazole, in particular the two cis dioxolane diastereomers of the sec-butyl (R,S)-isomer, and to phosphate and sulfate derivatives thereof is disclosed. Pharmaceutical compositions containing these compounds and their use for the treatment of fungal infection are also disclosed.

2R, 4S, R, S- and 2S, 4R, R, S-hydroxyitraconazole

Pharmaceutical compositions are disclosed utilizing the optically pure (-) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dyspepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (-) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.

Compositions of optically pure (-) norcisapride and another therapeutic

Methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders caused by gastrointestinal motility dysfunction. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

Growing community of inventors

Worcester, MA, United States of America

John R McCullough